Oligonucleotide IMT504 effect on Mesenchymal stem cells in type 1 diabetes mouse model

MARIA SILVIA BIANCHI; ALEJANDRO D MONTANER ; MARIA ESTEFANIA BIANCHI; GOMEZ BUSTILLO SOFIA; VICTORIA LUX LANTOS

buenos aires

Congreso; Latin American Society of developmental biology meeting 2019; 2019

Latin American Society of developmental biology

Type 1 diabetes (T1D) is a multifactorial autoimmune disease in which insulin-producing pancreatic β cells are destroyed. No effective clinical interventions for T1D are currently available and patients are lifelong treat with insulin. New innovative approaches are needed to treat T1D. Different strategies to modulate immunological response and restore β cell mass have been performed, although limited by the availability of transplants and chronic immunosuppression. An exciting alternative consist in using therapeutic agents that can stimulate endogenous cells. Mesenchymal stem cells (MSCs) are multipotent cells characterized for their ability to promote immune-modulation, tissue regeneration, and homeostasis. IMT504 is the prototype of the PyNTTTTGT family of immunomodulatory oligonucleotides (ODNs) known for their regenerative properties and effective in lowering glycaemia in non-obese diabetic (NOD) mice. Here, we investigate its action on MSC in NOD mice model. Bone marrow MSCs from NOD mice were treated, in vitro, with different doses of IMT504 (0.5, 1.5, 4, 6.5 and 10.5 µg/ml). Fibroblasts colony forming units (CFU-F) that originate MSCs, viability and migration assays were assessed. It was determine that 0.5 µg/ml of IMT504 stimulated MSCs (68 CFU-F/8*105 seed cells, p